A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|May 20, 2025
Pharmacist Involvement in Clinical Research and the FINEARTS-HF Trial
Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota
Advertisement
Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota. Vardeny discusses her own career path, the importance of mentors, and pharmacist involvement in clinical research, such as her work with the FINEARTS-HF study of finerenone in heart failure.
Show Notes:
Advertisement
Related to this article
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5